Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$155.29 USD

155.29
1,094,683

+0.46 (0.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $155.34 +0.05 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Urmimala Biswas headshot

5 Value Stocks Based on Discounted PEG to Buy Now

by Urmimala Biswas

Here are five stocks, OLN, DGX, EQNR, TECK, and GS that qualify the screening.

Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Quest Diagnostics (DGX) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Quest Diagnostics (DGX) has been struggling lately, but the selling pressure may be coming to an end soon.

Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) third-quarter results are likely to reflect continued strength across its business segments.

Quest Diagnostics (DGX) Q3 Earnings Top Estimates, View Up

by Zacks Equity Research

Quest Diagnostics (DGX) notes that in late summer it experienced some softness in the base business across the country but recovered in September.

Quest Diagnostics (DGX) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 33.78% and 12.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Quest Diagnostics (DGX) Ahead of Earnings?

by Zacks Equity Research

Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ResMed (RMD) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Strong customer demand and new product launches are likely to contribute to growth in the fiscal first quarter for ResMed (RMD).

QIAGEN (QGEN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

New product approvals, partnerships in the diagnostic solutions category and sustained success in other product areas are likely to have contributed to QIAGEN's (QGEN) growth.

Quest Diagnostics (DGX) Base Arm Recovers, Testing Sales Grow

by Zacks Equity Research

Quest Diagnostics (DGX) is hopeful about the fact that COVID-19 testing remains critical as employees are returning to the workplace and students to the classroom.

Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics (DGX) Enhances Lab Experience With Facility

by Zacks Equity Research

Quest Diagnostics (DGX) new facility is fully operational and will empower better health for the patients and clients in the seven states the lab serves.

COVID Test Demand to Aid Quest Diagnostics (DGX) Q3 Earnings

by Zacks Equity Research

In terms of strategic acquisitions, Quest Diagnostics (DGX) is likely to have secured high returns in Q3 from the acquisition of Mercy's outreach laboratory services business.

The Zacks Analyst Blog Highlights: Abbott Laboratories, UnitedHealth, Quest, and West Pharmaceutical

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott Laboratories, UnitedHealth, Quest, and West Pharmaceutical

Growing COVID-19 Testing Demand to Boost Abbott's (ABT) Q3 Earnings

by Zacks Equity Research

Through July to September, Abbott's (ABT) Diagnostic business is likely to have benefited from the significant surge in the new COVID-19 case counts.

Thermo Fisher (TMO) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Thermo Fisher's (TMO) recent launches within Chromatography and Mass Spectrometry like Thermo Scientific Orbitrap IQ-X Tribrid Mass Spectrometer should have contributed to its Q3 top line.

Zacks.com featured highlights include: Hibbett, O'Reilly Automotive, The Interpublic Group of Companies and Quest Diagnostics

by Zacks Equity Research

Zacks.com featured highlights include: Hibbett, O'Reilly Automotive, The Interpublic Group of Companies and Quest Diagnostics

Sumit Singh headshot

4 Stocks That Stand Out on Attractive Interest Coverage Ratio

by Sumit Singh

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Hibbett (HIBB), O'Reilly Automotive (ORLY), The Interpublic Group of Companies (IPG) and Quest Diagnostics (DGX) are sound enough to meet financial obligations.

Urmimala Biswas headshot

5 Finest PEG Stocks Based on Hybrid Investment Strategy

by Urmimala Biswas

Here are five out of the 14 stocks, TSCDY, REGN, DGX, EQNR and MAKSY that qualified the screening.

Quest Diagnostics' (DGX) Efforts to Reduce Health Inequities

by Zacks Equity Research

Quest Diagnostics' (DGX) efforts to support AHA will boost innovative solutions like the Scholars programs, hypertension control and COVID-19 rapid response.

Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Faster adoption of digital health and an improved business environment are expected to have contributed to Walgreens' (WBA) fourth-quarter performance.

Down 9.4% in 4 Weeks, Here's Why Quest Diagnostics (DGX) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Quest Diagnostics (DGX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Quest Diagnostics' (DGX) Base Volumes Rise, Testing Recovers

by Zacks Equity Research

Contributions from new hospital lab management contracts as well as people returning to the healthcare system aid Quest Diagnostics (DGX).

Riya Anand headshot

3 High-Potential MedTech Stocks With More Than 50% Growth YTD

by Riya Anand

Stocks like West Pharmaceuticals Services (WST), Maravai LifeSciences (MRVI) and Option Care Health (OPCH) have gained stupendously year to date.